Reata's lead program is in clinical trials for chronic kidney disease

Overview

Reata has a robust pipeline of drug candidates and discovery programs built around two proprietary technology platforms – the AIMs and our protein folding chaperone technology. Reata's lead molecule, bardoxolone methyl, formerly known as RTA 402, has achieved proof of concept in chronic kidney disease. Chronic kidney disease is an area of enormous unmet medical need with significant commercial potential.

	Pre-Clinical	Phase I	Phase II	Phase III
Bardoxolone Methyl Renal/CV (Oral Once Daily AIM) Chronic Kidney Disease
AIM for CNS diseases (Oral Once Daily)   Multiple Sclerosis
AIM for Respiratory Diseases (Oral Once Daily)   COPD
RTA 801 (SOD1 Protein Folding Stabilizer)   Amyotrophic Lateral Sclerosis (ALS)